1. U.S. Food and Drug Administration. MedWatch Safety Alerts for Human Medical Products. [cited June 1 2017]. Available from: URL: https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/default.htm
2. Ellis SG, Kereiakes DJ. A Bioresorbable Everolimus-Eluting Scaffold Versus a Metallic Everolimus-Eluting Stent III - ABSORB III. Presented by Ellis SG and Kereiakes DJ. American College of Cardiology Annual Scientific Session (ACC 2017). [cited June1 2017]. Available from: URL: http://www.acc.org/latest-in-cardiology/clinical-trials/2015/10/10/21/09/absorb-iii#sthash.GJeEbjNK.dpuf
3. O’Riordan M. Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions. [cited June 1 2017]. Available from: URL: https://www.tctmd.com/news/absorb-europe-when-how-and-whom-beleaguered-bvs-being-used-after-restrictions
4. Therapeutic Goods Administration. Absorb Bioresorbable Vascular Scaffold System. [cited June 1 2017]. Available from: URL: https://www.tga.gov.au/alert/absorb-bioresorbable-vascular-scaffold-system
5. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents